Texas Permanent School Fund lowered its position in shares of Eli Lilly and Company (NYSE:LLY) by 2.5% during the first quarter, according to its most recent disclosure with the SEC. The institutional investor owned 283,694 shares of the company’s stock after selling 7,323 shares during the period. Texas Permanent School Fund’s holdings in Eli Lilly and Company were worth $23,862,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Silvercrest Asset Management Group LLC boosted its position in Eli Lilly and Company by 18.3% in the fourth quarter. Silvercrest Asset Management Group LLC now owns 9,681 shares of the company’s stock valued at $712,000 after buying an additional 1,500 shares during the period. Envestnet Asset Management Inc. boosted its position in shares of Eli Lilly and Company by 42.3% in the fourth quarter. Envestnet Asset Management Inc. now owns 187,654 shares of the company’s stock valued at $13,804,000 after buying an additional 55,767 shares in the last quarter. Tyers Asset Management LLC purchased a new position in shares of Eli Lilly and Company during the fourth quarter valued at approximately $4,288,000. Parallel Advisors LLC purchased a new position in shares of Eli Lilly and Company during the fourth quarter valued at approximately $1,384,000. Finally, InterOcean Capital LLC purchased a new position in shares of Eli Lilly and Company during the fourth quarter valued at approximately $209,000. Institutional investors and hedge funds own 75.41% of the company’s stock.

Shares of Eli Lilly and Company (NYSE LLY) traded up 0.39% during mid-day trading on Friday, hitting $84.35. 2,005,749 shares of the stock were exchanged. Eli Lilly and Company has a 12 month low of $64.18 and a 12 month high of $86.72. The stock has a market cap of $93.07 billion, a PE ratio of 40.75 and a beta of 0.35. The stock’s 50 day moving average is $80.49 and its 200-day moving average is $79.95.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Tuesday, April 25th. The company reported $0.98 earnings per share for the quarter, topping analysts’ consensus estimates of $0.96 by $0.02. The business had revenue of $5.23 billion during the quarter, compared to analysts’ expectations of $5.22 billion. Eli Lilly and Company had a return on equity of 26.64% and a net margin of 10.13%. The company’s revenue was up 7.5% compared to the same quarter last year. During the same period in the prior year, the business posted $0.83 EPS. On average, analysts anticipate that Eli Lilly and Company will post $4.12 EPS for the current year.

The company also recently announced a quarterly dividend, which will be paid on Friday, September 8th. Investors of record on Tuesday, August 15th will be issued a dividend of $0.52 per share. This represents a $2.08 dividend on an annualized basis and a yield of 2.47%. The ex-dividend date of this dividend is Friday, August 11th. Eli Lilly and Company’s dividend payout ratio (DPR) is 100.48%.

COPYRIGHT VIOLATION WARNING: “Texas Permanent School Fund Has $23.86 Million Position in Eli Lilly and Company (LLY)” was posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this article on another site, it was stolen and reposted in violation of US and international copyright and trademark legislation. The legal version of this article can be read at https://www.thecerbatgem.com/2017/07/16/texas-permanent-school-fund-has-23-86-million-position-in-eli-lilly-and-company-lly-updated.html.

A number of research firms have commented on LLY. Citigroup Inc. reissued a “buy” rating and issued a $100.00 price target on shares of Eli Lilly and Company in a research note on Thursday, April 6th. Zacks Investment Research raised shares of Eli Lilly and Company from a “hold” rating to a “buy” rating and set a $94.00 price target for the company in a research note on Tuesday, April 4th. Credit Suisse Group reaffirmed a “buy” rating on shares of Eli Lilly and Company in a research note on Tuesday, March 21st. Jefferies Group LLC reaffirmed a “buy” rating and issued a $97.00 price objective on shares of Eli Lilly and Company in a research note on Monday, April 10th. Finally, Piper Jaffray Companies reaffirmed a “buy” rating and issued a $100.00 price objective on shares of Eli Lilly and Company in a research note on Monday, April 17th. Two research analysts have rated the stock with a sell rating, seven have assigned a hold rating and eleven have given a buy rating to the company’s stock. Eli Lilly and Company has a consensus rating of “Hold” and a consensus price target of $87.61.

In other Eli Lilly and Company news, VP Michael J. Harrington sold 22,833 shares of the stock in a transaction dated Friday, June 9th. The stock was sold at an average price of $79.97, for a total value of $1,825,955.01. Following the sale, the vice president now owns 62,056 shares of the company’s stock, valued at approximately $4,962,618.32. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, major shareholder Lilly Endowment Inc sold 210,000 shares of the stock in a transaction dated Thursday, June 22nd. The shares were sold at an average price of $84.43, for a total value of $17,730,300.00. Following the completion of the sale, the insider now directly owns 124,265,804 shares in the company, valued at approximately $10,491,761,831.72. The disclosure for this sale can be found here. Insiders have sold a total of 474,733 shares of company stock valued at $39,634,487 over the last 90 days. 0.20% of the stock is currently owned by company insiders.

About Eli Lilly and Company

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Institutional Ownership by Quarter for Eli Lilly and Company (NYSE:LLY)

Receive News & Stock Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related stocks with our FREE daily email newsletter.